Know Cancer

or
forgot password

A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a Continuous 7-Day Intravenous Infusion in Patients With Advanced Solid Malignancies


Phase 1
18 Years
N/A
Not Enrolling
Both
Solid Tumours

Thank you

Trial Information

A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a Continuous 7-Day Intravenous Infusion in Patients With Advanced Solid Malignancies


Inclusion Criteria:



- Histological or cytological confirmation of a solid, malignant tumour

Exclusion Criteria:

- Participation in an investigational drug study within 21 days prior to entry or who
have not recovered from the effects of an investigational study drug

- Treatment with radiotherapy/chemotherapy with 4 weeks of first dose

- Recent major surgery within 4 weeks prior to entry to the study

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Safety and Tolerability

Outcome Time Frame:

Assessed at each visit

Principal Investigator

David Kerr, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Oxford

Authority:

United Kingdom: Medicines and Healthcare Products Regulatory Agency

Study ID:

D1531C00003

NCT ID:

NCT00497679

Start Date:

August 2006

Completion Date:

July 2007

Related Keywords:

  • Solid Tumours
  • advanced solid tumours

Name

Location